Bremelanotide (PT-141) is a synthetic peptide analogue of alpha-melanocyte-stimulating hormone (α-MSH). It is a small peptide hormone that acts on melanocortin receptors in the brain and body.
Bremelanotide is currently approved by the FDA for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. It is the first and only FDA-approved drug for the treatment of HSDD in women.
Bremelanotide is generally well-tolerated, but some people may experience side effects such as:
- Flushing
- Nausea
- Headache
- Dizziness
- Hypotension
- Injection site reactions
In rare cases, bremelanotide can cause more serious side effects, such as:
- Seizures
- Allergic reactions
- Liver toxicity
Bremelanotide is not recommended for people with certain medical conditions, such as:
- Cardiovascular disease
- Liver disease
- Kidney disease
- Seizure disorders
- Mental health disorders
Common side effects of bremelanotide
The most common side effects of bremelanotide are:
- Flushing (redness and warmth of the face, neck, and chest)
- Nausea
- Headache
- Dizziness
These side effects are usually mild and go away on their own within a few hours.
Less common side effects of bremelanotide
Less common side effects of bremelanotide include:
- Hypotension (low blood pressure)
- Injection site reactions (redness, pain, swelling, or itching at the injection site)
- Vomiting
- Constipation
- Diarrhea
- Fatigue
- Insomnia
- Anxiety
- Depression
- Decreased libido
Rare side effects of bremelanotide
Rare side effects of bremelanotide include:
- Seizures
- Allergic reactions (such as hives, swelling of the face, throat, tongue, or lips, difficulty breathing, or dizziness)
- Liver toxicity
The side effects of bremelanotide are generally mild and well-tolerated. However, it is important to be aware of the potential risks and benefits of bremelanotide before taking it. If you experience any side effects, talk to your doctor.
